Decreased monocyte-mediated cytostasis of human cancer cell in patients with lung cancer
- 9 Downloads
- 5 Citations
Summary
In vivo animal studies support the concept that monocytes and macrophages are important in the immune surveillance of oncogenesis and that in vitro activated murine macrophages are cytocidal for tumour cells. In this study, the tumour cell cytotoxic activity of human peripheral blood monocytes was examined by measuring the inhibition of 3H-thymidine uptake in the human cancer cell line, established in our laboratory from human squamous cell lung cancer. The monocytes from 8 of the 31 lung cancer patients (26%) showed a percentage growth inhibition of less than 69.8%, which exceeded the 95% confidence limits of the percentage growth inhibition observed with healthy control monocytes. On the other hand, among the 16 sarcoidosis and the 8 tuberculosis cases no value was below 69.8%. However, there was no significant difference between the growth inhibition and the clinical stages or histological type. When OK-432, a Streptococal agent, was administered in vivo to patients with lung cancer, an elevation of the growth inhibition was observed in 7 out of 8 patients. It was confirmed that the tumour cell cytostatic activity of the monocyte is suppressed in patients with lung cancer, and these monocyte deficits hinder the inhibition of tumour growth and metastasis.
Keywords
Lung Cancer Tuberculosis Sarcoidosis Lung Cancer Patient Human Cancer CellPreview
Unable to display preview. Download preview PDF.
References
- 1.Brightmore TGL, Greening WP, Hamlin I (1970) An analysis of clinical and histopathological feature in 101 cases of carcinoma of breast in women under 35 years of age. Br J Cancer 24:644Google Scholar
- 2.Cameron DJ, O'Brien P (1982) Cytotoxicity of cancer patient's macrophages for tumour cells. Cancer 50:498Google Scholar
- 3.Eccles SA, Alexander P (1974) Macrophage content of tumours in relation to metastatic spread and host immune reaction. Nature 250:667Google Scholar
- 4.Fidler IJ (1974) Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages. Cancer Res 34:1074Google Scholar
- 5.Fischer DG, Golightly MG, Koren HS (1983) Potentiation of the cytolytic activity of peripheral blood monocytes by lymphokines and interferon. J Immunol 130:1220Google Scholar
- 6.Furth R, Cohn ZA, Hirsch JG, Humphrey JH, Spectro WG, Langevoort HL (1972) The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull WHO 46:845Google Scholar
- 7.Gerrard TL, Terz JJ, Kaplan AM (1980) Cytotoxicity to tumour cells of monocytes from normal individuals and cancer patients. Int J Cancer 26:585Google Scholar
- 8.Hammerstöm J, Unsgaard G, Lamvik J (1979) Activation of human monocyte by mediators from lymphocytes stimulated with Corynebacterium parvum. Acta Pathol Microbiol Immunol Scand [C] 87:167Google Scholar
- 9.Hanna MG, Nettesheim P, Snodgrass MH (1971) Decreasing immune competence and development of reticulum cell sarcomas in lymphatic tissue of aged mice. J Natl Cancer Inst 46:809Google Scholar
- 10.Israel L (1974) Report on 414 cases of human tumours treated with corynebacteria. In: Corynebacterium parvum: applications in experimental and clinical oncology. Plenum Press, New York p 389Google Scholar
- 11.Israel L, Edelstein R, Depierre A, Dimitrov N (1975) Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: A preliminary report of clinical and biologic findings. J Natl Cancer Inst 55:29Google Scholar
- 12.Keller R (1976) Promotion of tumour growth in vivo by antimacrophage agents. J Natl Cancer Inst 57:1355Google Scholar
- 13.Kleinerman ES, Zwelling LA, Howser D, Barlock A, Young RC, Decker JM, Bull J, Muchmore AV (1980) Defective monocyte killing in patients with malignacies and restoration of function during chemotherapy. Lancet II:1102Google Scholar
- 14.Levy MH, Wheelock EF (1974) The role of macrophages in defence against neoplstic disease. Advan Cancer Res 20:131Google Scholar
- 15.Mantovani A, Polentarutti N, Peri G, Shavit ZB, Vecchi A, Bolis G, Mangioni C (1980) Cytotoxicity on tumour cells of peripheral blood monocytes and tumour-associated macrophages in patients with ascites ovarian tumours. J Natl Cancer Inst 64:1307Google Scholar
- 16.Matthes ML (1976) Induction of macrophage-mediated cytotoxicity. In: Immunobiology of the macrophage. Academic Press, New York San Francisco London p 464Google Scholar
- 17.Nakata Y, Kataoka M, Yamashita T, Sato T, Noda N, Nakata Y, Hiraki S, Ohnoshi T, Kimura I (1980) Monocyte function in patients with bronchogenic carcinoma. Lung Cancer (Japan) 20:293Google Scholar
- 18.Noda N (1983) Immunochemotherapy for lung cancer. I. Evaluation of the immunopotentiators OK-432 and PSK. Okayama Igakkai Zashi 95:1137Google Scholar
- 19.Noda N (1983) Immunochemotherapy for lung cancer. II. Effects of the Streptococcal agent, OK-432, on monocyte functions in lung cancer patients. Okayama Igakkai Zashi 95:1145Google Scholar
- 20.Peri G, Polentarutti N, Sessa C, Mangioni C, Mantovani A (1981) Tumouricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: Augmentation by interferon, lymphokines and endotoxin. Int J Cancer 28:143Google Scholar
- 21.Russell SW, Gillespie G, Hansen B, Cochrane CG (1976) Inflammatory cells in solid murine neoplasms. II. Cell types found throughout the course of Moloney sarcoma regression or progression. Int J Cancer 18:331Google Scholar
- 22.Russel SW, McIntosh AT (1977) Macrophages isolated from regressing Moloney sarcomas are more cytotoxic than those recovered from progressing sarcomas. Nature 268:69Google Scholar
- 23.Scott MT (1974) Corynebacterium parvum as an immunotherapeutic anticancer agent. Semin Oncol 1:367Google Scholar
- 24.Underwood JCE (1974) Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br J Cancer 30:538Google Scholar
- 25.Yanagawa E, Uchida A, Kokoschka EM, Micksche M (1984) Natural cytotoxicity of lymphocytes and monocytes and its augmentation by OK-432 in melanoma patients. Cancer Immunol Immunother 16:131Google Scholar